Johnson & Johnson (NYSE: JNJ) recently announced positive results from a phase 2 study of its RSV vaccine candidate. In this Motley Fool Live video recorded on Oct. 6, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J set a high bar for Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) to top.
In June, 23andMe (NASDAQ: ME) officially finished the process of going public via a special purpose acquisition company (SPAC). While no one knows where shares of the genetic-testing company will trade in the near term, investors have a better idea of where 23andMe stock can trade over the long term. Over the course of years, stock prices tend to correlate with cash flows and, therefore, if the company dramatically increases it cash flows, the stock price could head higher as well.
Dr. Francis Collins, Outgoing NIH Director, joins Yahoo Finance’s Anjalee Khemlani to discuss Covid-19 vaccine production, drug development research, and misinformation surrounding Covid-19 vaccines.